In isolated dog heart,
Theo-Esberiven 0.1 mg, which contains 12 mg
proxyphylline, 2.5 mg
rutin and 5 mg Melilotus extract, and
proxyphylline (12 mg) increased coronary blood flow (CBF) and was associated with increased heart rate (HR) and myocardial contractile force (MCF). The effect of
Theo-Esberiven on CBF was about 1.7 times higher than that of
proxyphylline.
Theo-Esberiven did not significantly affect myocardial oxygen consumption (QO2) and redox potential (deltaEh), while
proxyphylline aggravated myocardial metabolisms, as determined from these parameters.
Esberiven 0.1 ml, which contains 2.5 mg
rutin and 5 mg Melilotus extract, slightly but signficantly increased CBF and decreased QO2 and deltaEh without changing HR and MCF. In situ, intra-coronary injection of either
Theo-Esberiven or
proxyphylline resulted in a dose-dependent increase in left circumflex coronary flow (LCCF). The effect of
Esberiven on LCCF was much less and was slight at the higher doses.
Intravenous injection of
Theo-Esberiven (0.1 ml/kg) increased LCCF. Besides this change, marked fall in blood pressure and
tachycardia were induced by both
Theo-Esberiven and
proxyphylline without the change in dP/dtmax.
Esberiven by the same route led to the decrease in blood pressure associated with HR and dP/dtmax. These results indicate that
Theo-Esberiven may be appropriately prescribed for
ischemic heart diseases.